AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
NCT03986541
Colonic Diseases, Colorectal Cancer Stage IV
Huddersfield, West Yorkshire, United Kingdom
View Trial DetailsNCT Number: NCT05164419
We retrospectively looks at the impact of the margin status and its size in mm on the recurrence rate in colo-rectal liver metastasis surgery.
Looking for future studies?
Notify Me18 year–100 year
All sexes
Observational
Main objective : evaluation the margin status (<1mm, 1-4mm, 5-9mm, >10mm) on the survival and recurrence in colo-rectal liver metastases surgery.
Secondary objectives include :
Evaluate potentiel effects of neo-adjuvant chemotherapy, portal embolisation, and evaluate potentiel bias such as size and number of liver metastases, TNM status of original tumor, timing between primary and metastasis, and extra-hepatic disease.
Methods :
A retrospective cohort study is built where all patients undergoing liver surgery for colorectal liver metastases between 2011 and 2015 are analysed. Subjects are separated in groups according to their margin status. The local and distal recurrence rates are measured and well as survival. Data is obtained through our hospital data management system. Inclusion criterias include age over 18, primary colorectal cancer metastatic to the liver, having undergone surgery between 2011 and 2015, available pathology reports with required data, available radiologic follow-up. Exclusion criterias include repeat liver resection, documented grossly positive margins (R2 resection), and unavailable pathologic information and follow-up. Using survival as primary outcome (Kaplan Meier) and considering 25% potential loss to follow-up, we calculated a sample size. Since this a retrospective study, no patient is directly contacted. Data will is handled by the surgery resident responsible for the project as well as by research assistants. Statistical analysis are performed accordingly.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
Patient is dead or aline
Time frame: 2 years
Advent of recurrence in the liver parenchyma, measured by any time of medical imaging
Time frame: 2 years
Advent of recurrence anywhere other than liver, measured by any time of medical imaging
Université de Sherbrooke
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03986541
Colonic Diseases, Colorectal Cancer Stage IV
Huddersfield, West Yorkshire, United Kingdom
View Trial DetailsNCT06329700
Colonic Diseases, Colorectal Cancer Stage IV
View Trial DetailsNCT05550701
Colonic Diseases, Colorectal Cancer Stage IV
Harbin, Heilongjiang, China
View Trial DetailsNCT04715061
Colonic Diseases, Colorectal Cancer Stage IV
Sherbrooke, Quebec, Canada
View Trial Details